Australian Broker Call

Citi rates ALG as Buy (1) -

Momentum suggests an improving outlook for Ardent Leisure Group's outlook following weakness in December and January. Citi noted the slump is largely expected given coid surges and difficult comparables with key holidays falling on a Friday and Saturday. 

Looking ahead the broker expects inflationary pressures to factor into results, with increasing food and labour costs likely to impact. Citi expects price increases will be an option to offset pressures. 

The Buy rating and target price of $1.80 are retained. 

Target price is $1.80 Current Price is $1.39 Difference: $0.41
If ALG meets the Citi target it will return approximately 29% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates ARF as Neutral (3) -

Arena REIT's earnings were broadly in line with Macquarie. FY22 dividend guidance has been upgraded  by 1%, reflecting underlying portfolio strength. Operational metrics are indicative of solid fundamentals underpinning the Early Learning Centre sub-sector.

The REIT's rent review structure will drive growth in the medium term, the broker suggests. Valuation is a bit rich, but balancing out strong fundamentals and robust earnings growth, the broker retains Neutral. Target rises to $4.90 from $4.89.

Target price is $4.90 Current Price is $4.90 Difference: $0
If ARF meets the Macquarie target it will return approximately 0% (excluding dividends, fees and charges).

Current consensus price target is $4.27, suggesting downside of -10.2% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgan Stanley rates ARF as Equal-weight (3) -

Arena REIT reported a 1H profit and dividend broadly in-line with Morgan Stanley's forecast. Management increased FY22 DPS guidance to 16cpu from15.8cpu, versus the broker's forecast for 15.9cpu.

The analyst considers the REIT one of the better inflation hedges in the sector, with more than 75% of FY22/23 leases incorporating the higher of CPI or 3% annual reviews.

The Equal Weight rating and $4.18 target are retained. Industry view: In-line.

Target price is $4.18 Current Price is $4.90 Difference: minus $0.72 (current price is over target).
If ARF meets the Morgan Stanley target it will return approximately minus 15% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $4.27, suggesting downside of -10.2% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates BBN as Buy (1) -

Baby Bunting Group continues to explore growth opportunities and has suggested another upgrade to its current store expansion target of more than 110 locations, but Citi warns at its current pace the existing target won't be reached for around 6 years. 

Low presence in the clothing, food and nappies categories offer growth potential, and increased penetration of these categories could allow market share gains. The company appears well placed to outperform the small cap retail sector given a strong growth outlook. 

The Buy rating is retained and the target price increases to $6.22 from $6.11. 

Target price is $6.22 Current Price is $5.27 Difference: $0.95
If BBN meets the Citi target it will return approximately 18% (excluding dividends, fees and charges).

Current consensus price target is $6.39, suggesting upside of 23.3% (ex-dividends)

The company's fiscal year ends in July.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates BBN as Outperform (1) -

Baby Bunting's first half was in line with Macquarie, with 10% sales growth underpinned by online outperformance. Margins growth is supported by a continued increase in private label and exclusive product sales.

The second half has started well, and store network growth targets remain unchanged. The broker retains Outperform, supported by current performance and investment to support long-term growth.

Target rises to $6.21 from $6.11.

Target price is $6.21 Current Price is $5.27 Difference: $0.94
If BBN meets the Macquarie target it will return approximately 18% (excluding dividends, fees and charges).

Current consensus price target is $6.39, suggesting upside of 23.3% (ex-dividends)

The company's fiscal year ends in July.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgan Stanley rates BBN as Overweight (1) -

Morgan Stanley assesses another high-quality (1H) result for Baby Bunting which was well ahead of consensus. Momentum into the 2H was also considered impressive.

The gross profit and gross margin (a beat versus the broker's estimates) demonstrated the benefits of scale and supply chain investment.

Overweight. Target is $6.90. Industry view: In-line.

Target price is $6.90 Current Price is $5.27 Difference: $1.63
If BBN meets the Morgan Stanley target it will return approximately 31% (excluding dividends, fees and charges).

Current consensus price target is $6.39, suggesting upside of 23.3% (ex-dividends)

The company's fiscal year ends in July.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates BBN as Add (1) -

Baby Bunting Group reported a strong first half result with store sales growth up 6.8% compared to Morgans' expected 2.3% and up 21.8% on a two-year basis, and momentum appears to have continued into the second half. 

While a gross margin increase to 39.3% exceeded expectations, expect margin contraction in the second half on seasonality as well as the reset of hedging and freight contracts.

Looking ahead, potential for further growth in broader baby products was indicated, offering potential to further drive comparable store sales growth. The broker believes opportunity exists to win a greater share of the $5.1bn baby goods market. 

The Add rating is retained and the target price decreases to $6.00 from $6.20.

Target price is $6.00 Current Price is $5.27 Difference: $0.73
If BBN meets the Morgans target it will return approximately 14% (excluding dividends, fees and charges).

Current consensus price target is $6.39, suggesting upside of 23.3% (ex-dividends)

The company's fiscal year ends in July.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates BBN as Buy (1) -

Baby Bunting's FY22 December-half result seriously outpaced Ord Minnett's forecast, the company recording above-market sales growth, higher gross profit margins and strong cost discipline.

EPS forecasts are upgraded 5.9% in FY22, 2.6% in FY23 and 3% in FY24 to reflect the strong result.

The broker spies room for building operating margins, increased online sales penetration, organic sales growth and store rollouts.

Buy rating retained. Target price eases to $6.60 from $6.65.

Target price is $6.60 Current Price is $5.27 Difference: $1.33
If BBN meets the Ord Minnett target it will return approximately 25% (excluding dividends, fees and charges).

Current consensus price target is $6.39, suggesting upside of 23.3% (ex-dividends)

The company's fiscal year ends in July.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates CIM as Neutral (3) -

Cimic Group's 2021 profit was toward the low-end of the guidance range, and a -3% miss versus the estimate by UBS and consensus. A  6% beat for Construction earnings was insufficient to counter a miss for Thiess equity accounted profits.

Further cash outflows from Leighton Asia and reduced debtor factoring financing contributed to disappointing cash flows, explains the analyst.

The target price falls to $16.50 from $22.50 partly due to lower target multiples, higher than expected debt levels, as well
as the partial divestment of the group's stake in Ventia.

Target price is $16.50 Current Price is $15.63 Difference: $0.87
If CIM meets the UBS target it will return approximately 6% (excluding dividends, fees and charges).

Current consensus price target is $20.34, suggesting upside of 30.5% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY23:

Forecast for FY24:

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates CSL as Hold (3) -

Following industry feedback and peer results, Ord Minnett lowers its target price for CSL to $285 from $315.

The analyst lowers the forecast for gross margins in the plasma division, as covid has wrought a structural decline in per-centre collections and a lift in donor fees. A weaker US uptake from the Seqirus (flu) division also weighed on the forecast.

A cautious Hold rating is maintained given the protracted pandemic impacts and questions over when demand will recover, explains the broker.

Target price is $285.00 Current Price is $248.50 Difference: $36.5
If CSL meets the Ord Minnett target it will return approximately 15% (excluding dividends, fees and charges).

Current consensus price target is $312.94, suggesting upside of 28.5% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates IAG as Buy (1) -

Citi notes while Insurance Australia Group's first half underlying insurance margin of 13.6% may initially disappoint, a seemingly conservative margin should allow for a much stronger second half margin. 

The first half margin has been impacted by headwinds that look to unwind moving forward, including front loaded expenses and one-off investments. Further, 6.2% growth in the half was the best result in a long time time and supported a guidance increase. 

The Buy rating is retained and the target price increases to $5.75 from $5.60.

Target price is $5.75 Current Price is $4.74 Difference: $1.01
If IAG meets the Citi target it will return approximately 21% (excluding dividends, fees and charges).

Current consensus price target is $5.09, suggesting upside of 7.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates IAG as Outperform (1) -

Macquarie assumes the market was expecting the worst from Insurance Australia Group's result given a positive share price response, because the negatives outweighed the positives in the broker's view.

Underlying trends remain "perplexing", the broker suggests, and to achieve FY24 margin targets, not only does IAG need to achieve 10% margin in the Intermediated  division, but margin repair is beginning to be required in Home and Motor as well.

An upgrade to gross written premium guidance is also misleading, as it's down to forex assistance. Still, on cheap valuation the broker retains Outperform, mindful of short term risks. Target falls to $5.00 from $5.10.

Target price is $5.00 Current Price is $4.74 Difference: $0.26
If IAG meets the Macquarie target it will return approximately 5% (excluding dividends, fees and charges).

Current consensus price target is $5.09, suggesting upside of 7.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgan Stanley rates IAG as Underweight (5) -

Morgan Stanley notes a beat for Insurance Australia Group's 1H margins, and upgraded guidance for gross written premium growth. However, it's felt several risks to earnings and cost of capital are not currently incorporated into the share price.

The analyst reminds investors the margin still fell year-on-year, and claims inflation remains a risk heading into 2022. Moreover, the  reported margin was not as strong with catastrophe costs and reserve headwinds.

The Underweight rating is kept while the target rises to $3.90 from $3.80. Industry view: Attractive.

Target price is $3.90 Current Price is $4.74 Difference: minus $0.84 (current price is over target).
If IAG meets the Morgan Stanley target it will return approximately minus 18% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $5.09, suggesting upside of 7.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates IAG as Buy (1) -

Insurance Australia Group's FY22 December-half cash insurance earnings outpaced Ord Minnett's forecasts but the insurance reported result fell a touch shy due to higher-than-estimated perils costs and reserve additions.

The broker appreciates the company's strong gross written premiums and management noted that rate rises were pushing underlying margins higher, despite weakness in reported margins.

Buy rating retained. Target price edges up to $5.50 from $5.45.

Target price is $5.50 Current Price is $4.74 Difference: $0.76
If IAG meets the Ord Minnett target it will return approximately 16% (excluding dividends, fees and charges).

Current consensus price target is $5.09, suggesting upside of 7.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates IAG as Sell (5) -

Despite most metrics contained within 1H results for Insurance Australia Group either meeting or exceeding consensus estimates, UBS is concerned over a fall in the underlying insurance margin to 13.6% from 14.2% in the previous corresponding period.

The analyst sees claims inflation rising for several insurance lines and observes compliance and IT cost pressures.

The broker retains its below-consensus outlook, and maintains its Sell rating and $4.20 target price. 

Target price is $4.20 Current Price is $4.74 Difference: minus $0.54 (current price is over target).
If IAG meets the UBS target it will return approximately minus 11% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $5.09, suggesting upside of 7.8% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates MFG as Neutral (3) -

Macquarie has cut its target for Magellan Financial to $18.50 from $20.00 on concern over -$5.5bn in outflows so far in 2022. Ongoing volatility presents further outflow risk and thus little scope for a re-rating.

On a sum-of-the-parts methodology, the broker does not yet see valuation as sufficiently compelling. Neutral retained.

Target price is $18.50 Current Price is $18.11 Difference: $0.39
If MFG meets the Macquarie target it will return approximately 2% (excluding dividends, fees and charges).

Current consensus price target is $18.41, suggesting upside of 0.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: -0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgan Stanley rates MFG as Underweight (5) -

Magellan Financial Group has reported outflows for January and February 2022, confirming Morgan Stanley's dim view of the company's prospects.

The broker says the data implies -$7bn of outflows in global equities over the period, the bulk coming in February following portfolio management adjustments.

Given the bulk of the fund's clients are large, lumpy non-Australian institutions, the broker spies the threat of continued margin pressure in retail channels.

Underweight rating at $17.20 target price retained.

Target price is $17.20 Current Price is $18.11 Difference: minus $0.91 (current price is over target).
If MFG meets the Morgan Stanley target it will return approximately minus 5% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $18.41, suggesting upside of 0.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: -0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates MFG as Sell (5) -

Following a funds under management (FUM) update by Magellan Financial Group, UBS believes risks remain skewed to the downside.The level of sustainable FUM, potential fee reductions to stem retail outflows, and staff retention are all considered worries.

The group revealed net outflows of -$5.5bn since the start of January, which suggests to the broker institutional global equity outflows are tracking significantly higher at around -$6.5-7bn. 

The Sell rating and $17 target price are retained.

Target price is $17.00 Current Price is $18.11 Difference: minus $1.11 (current price is over target).
If MFG meets the UBS target it will return approximately minus 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $18.41, suggesting upside of 0.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: -0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates MGR as Outperform (1) -

Mirvac's first half investment earnings were below Macquarie's expectations. albeit FY22 guidance was reaffirmed, aided by higher commercial development profits.

A review of the company's commercial development and apartment pipeline provides confidence in catalysts for operating earnings growth over FY23-FY27, the broker notes.

The broker re-bases investment earnings, but on a strong development outlook, and Mirvac trading at a discount to net tangible asset value, Outperform retained. Target falls to $2.97 from $3.15.

Target price is $2.97 Current Price is $2.47 Difference: $0.5
If MGR meets the Macquarie target it will return approximately 20% (excluding dividends, fees and charges).

Current consensus price target is $3.10, suggesting upside of 23.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates NST as Buy (1) -

Underlying profit for Northern Star Resources of $108m was below UBS' expectations after a -$90m non-cash inventory cost. A 10cps dividend was in-line and management maintained production guidance. 

Despite labour pressures from the WA border closure, the broker backs the company to attain its targeted rate of 25% production growth in four years. The target price falls to $10.80 from $11.20. Buy.

Target price is $10.80 Current Price is $8.50 Difference: $2.3
If NST meets the UBS target it will return approximately 27% (excluding dividends, fees and charges).

Current consensus price target is $11.48, suggesting upside of 27.5% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgan Stanley rates REA as Overweight (1) -

Morgan Stanley feels fears around listings are overdone for REA Group and remain positive on the outlook. The Overweight rating is retained after a -19% year-to-date fall in share price, first half results that beat expectations and a positive start to the 2H.

The analyst sees a challenge for the company in maintaining existing growth rates over the longer term. Thus, in a hypothetical scenario, it's felt acquiring more of Move Inc, should the opportunity arise, would make financial and strategic sense.

The Target price falls to $178 from $182.50. Industry View: Attractive.

Target price is $178.00 Current Price is $136.11 Difference: $41.89
If REA meets the Morgan Stanley target it will return approximately 31% (excluding dividends, fees and charges).

Current consensus price target is $162.19, suggesting upside of 19.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates SQ2 as Buy (1) -

Citi resumes coverage on Block, noting the acquisition of Afterpay offers a value creation opportunity  that expands the new product development canvas for both parties and improves Block's product development capabilities. 

Citi expects the merge to be 50% gross profit accretive to Block's Cash app in FY23. The app retains 40m monthly average users, and downloads remain solid, but expect acquisition spend to increase with the inclusion of Verse, Cash App for Teens and tax filing capabilities. 

The broker reinitiates with a Buy rating and a target price of US$220.00.

Current Price is $147.45. Target price not assessed.

The company's fiscal year ends in December.

Forecast for FY22:

Forecast for FY23:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates STO as Buy (1) -

Ord Minnett downgrades Santos's target price to $9.15 from $9.35 after incorporating the 2021 reserve statement into its financial model.

Earnings estimates are largely steady, net present value estimates fall -2%.

Buy rating retained.

Target price is $9.15 Current Price is $7.42 Difference: $1.73
If STO meets the Ord Minnett target it will return approximately 23% (excluding dividends, fees and charges).

Current consensus price target is $8.91, suggesting upside of 15.3% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY21:

Forecast for FY22:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates UMG as Buy (1) -

United Malt Group reaffirmed expectations for processing volumes to approach pre-covid levels in FY22. Citi notes volume recovery, expansion initiatives and the transformation program are expected to drive 18% earnings compound annual growth through to FY24. 

Slow on-premise beer consumption in the US in January and February is likely, but low off-premise volumes could suggest a sustained shift toward on-premise has already taken place. Improvement continues in Australasia and distilling remains resilient. 

The Buy rating is retained and the target price increases to $5.00 from $4.90.

Target price is $5.00 Current Price is $4.14 Difference: $0.86
If UMG meets the Citi target it will return approximately 21% (excluding dividends, fees and charges).

Current consensus price target is $4.82, suggesting upside of 16.4% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates UMG as Outperform (1) -

Guidance was not provided at United Malt Group's AGM unlike last year due to a number of positive and negative factors, Macquarie notes, including covid, supply disruptions, the Canadian drought, and taking advantage of unprecedented malt prices, making forecasting difficult.

But management is confident that the outlook for the second and beyond is positive, provided we do not see a return of covid-related restrictions, and the broker is comfortable with its own current forecasts.

A downgrade to the industry multiple has the broker's target falling to $4.55 from $4.68, Outperform retained.

Target price is $4.55 Current Price is $4.14 Difference: $0.41
If UMG meets the Macquarie target it will return approximately 10% (excluding dividends, fees and charges).

Current consensus price target is $4.82, suggesting upside of 16.4% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates UMG as Buy (1) -

UBS assesses softer recent industry malt volumes (as a result of rising covid-19 cases) is temporary and maintains its Buy rating for United Malt Group, following recent AGM commentary.

Management reiterated transformation program earnings (EBITDA) benefits of $30m by FY24.

The broker lowers its target price to $5.05 from $5.10 and maintains a Buy rating.

Target price is $5.05 Current Price is $4.14 Difference: $0.91
If UMG meets the UBS target it will return approximately 22% (excluding dividends, fees and charges).

Current consensus price target is $4.82, suggesting upside of 16.4% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates URW as Neutral (3) -

UR Westfield reported 2021 adjusted recurring earnings in line with Macquarie but slightly ahead of guidance. 2022 guidance is below the broker's estimate but likely reflecting management conservatism due to covid.

Operational metrics imply improvement off a low base, particularly in the US, and the broker awaits the upcoming strategy day to learn more detail about US options.

Target rises to $5.71 from $5.44, Neutral retained.

Target price is $5.71 Current Price is $5.60 Difference: $0.11
If URW meets the Macquarie target it will return approximately 2% (excluding dividends, fees and charges).

The company's fiscal year ends in December.

Forecast for FY22:

Forecast for FY23:

This company reports in EUR. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: -0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates WTC as Initiation of coverage with an Accumulate rating (2) -

Ord Minnett resumes coverage of WiseTech Global after an 18-month hiatus with an Accumulate Rating and $51 target price (up from $27.45 in August 2020).

Wisetech is a global software-as-a-service provider to the logistics industry and offers a pure-play cloud approach vis-a-vis competitors.

Ord Minnett appreciates the company's track record of organic and inorganic growth, the company having posted a 38% compound annual growth rate since FY16.

Target price is $51.00 Current Price is $45.11 Difference: $5.89
If WTC meets the Ord Minnett target it will return approximately 13% (excluding dividends, fees and charges).

Current consensus price target is $46.78, suggesting upside of 2.5% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY22:

Forecast for FY23:

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources